Published in Physician Business Week, January 31st, 2006
"The characterization of clinically relevant latex allergens and the production of recombinant allergens is now well advanced, but this knowledge needs to be translated into new strategies for the safe and effective specific treatment of latex allergic diseases including asthma and anaphylaxis. The current status of latex allergy is discussed indicating a changing demographic paradigm," investigators in Australia reported.
"A new wave of latex allergy is emerging outside the healthcare setting with the widespread use of latex products. An increased prevalence in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.